Tapering infliximab dosages after temporary dose increase does not affect treatment survival in an established RA population (2008)
Vander Cruyssen, Bert,
WESTHOVENS, R,
DUREZ, P,
DE CLERCK, L,
PERETZ, A,
VERBRUGGEN, L,
...
Prediction models for disease: The effect of associations between markers on calculating the risk for disease by likelihood ratio products in SpA (2008)
Vander Cruyssen, Bert,
Wittoek, Ruth,
BOONEN, A,
De Vlam, Kurt,
VASTESAEGER, N,
NOEL, W,
...
Tapering infliximab dosages after temporary dose increase does not affect treatment survival in an established RA population (2008)
Vander Cruyssen, Bert,
WESTHOVENS, R,
DUREZ, P,
VAN DEN BOSCH, FILIP,
Mielants, Herman,
DE CLERCK, L,
...
Epidemiology of hip involvement in ankylosing spondylitis (2008)
Vander Cruyssen, Bert,
MUNOZ-GOMARIZ, E,
FONT, P,
MULERO, J,
De Vlam, Kurt,
BOONEN, A,
...
The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice (2007)
VANDER CRUYSSEN, BERT,
RIBBENS, C,
BOONEN, A,
Mielants, Herman,
De Vlam, Kurt,
LENAERTS, J,
...
Four year follow-up of infliximab in rheumatoid arthritis patients refractory to multiple dmard treatment: Long-term clinical effect and prediction of attrition (2006)
Vander Cruyssen, Bert,
WESTHOVENS, R,
DUREZ, P,
Van Den Bosch, Filip,
Mielants, Herman,
DE CLERCK, L,
...
Which patients with ankylosing spondylitis start anti-TNF-alpha therapy in daily clinical practice? (2006)
Vander Cruyssen, Bert,
Mielants, Herman,
BOONEN, A,
LENAERTS, J,
LESAFFRE, E,
De Vlam, Kurt,
...
Belgian patients with familial and sporadic ankylosing spondylitis differ in disease phenotype (2006)
De Vlam, Kurt,
VASTESAEGER, N,
BRASSEUR, JP,
BOONEN, A,
LENAERTS, J,
LESAFFRE, E,
...
Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity (2006)
Vander Cruyssen, Bert,
Van Looy, Stijn,
Wyns, Bart,
WESTHOVENS, R,
DUREZ, P,
Van Den Bosch, Filip,
...
Prediction of dose escalation for rheumatoid arthritis patients under infliximab treatment (2006)
Van Looy, Stijn,
Vander Cruyssen, Bert,
Meeus, Jeroen,
Wyns, Bart,
WESTHOVENS, R,
DUREZ, P,
...
DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment (2005)
Cruyssen, B,
Van Looy, S,
Wyns, B,
Westhovens, R,
Durez, P,
Malaise, M,
...
This study is based on an expanded access program in which 511 patients suffering from active refractory rheumatoid arthritis (RA) were treated with intravenous infusions of infliximab (3 mg/kg+...
Das28 correlates best with the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients (2005)
Vander Cruyssen, Bert,
Van Looy, Stijn,
WESTHOVENS, R,
DUREZ, P,
Van Den Bosch, Filip,
VEYS, EM,
...
DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment (2005)
Vander Cruyssen, Bert,
Van Looy, Stijn,
Wyns, Bart,
WESTHOVENS, R,
DUREZ, P,
MALAISE, M,
...
DAS28 is a robust measure of the physician's clinical judgment of response infliximab therapy (2005)
Vander Cruyssen, Bert,
Van Looy, Stijn,
Wyns, Bart,
WESTHOVENS, R,
DUREZ, P,
...
A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study (2005)
Durez, P.,
Corluy, L.,
Veys, E. M.,
De Clerck, L.,
Peretz, A.,
...
Objectives. To analyse the effect of a dose increase in patients with severe rheumatoid arthritis (RA) with insufficient clinical response to 3 mg/kg infliximab every 8 weeks. Methods. Patients...
A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study (2005)
Durez, P.,
Corluy, L.,
Veys, E. M.,
Clerck, L. De,
Peretz, A.,
...
Objectives. To analyse the effect of a dose increase in patients with severe rheumatoid arthritis (RA) with insufficient clinical response to 3 mg/kg infliximab every 8 weeks. Methods. Patients...
Timing of DAS28 in infliximab therapy: reply (2005)
Durez, P.,
Corluy, L.,
Veys, E.,
De Clerck, L.,
Peretz, A.,
...
Timing of DAS28 in infliximab therapy: reply (2005)
Durez, P.,
Corluy, L.,
Veys, E.,
De Clerck, L.,
Peretz, A.,
...